CN104120093A - Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof - Google Patents
Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof Download PDFInfo
- Publication number
- CN104120093A CN104120093A CN201310149307.3A CN201310149307A CN104120093A CN 104120093 A CN104120093 A CN 104120093A CN 201310149307 A CN201310149307 A CN 201310149307A CN 104120093 A CN104120093 A CN 104120093A
- Authority
- CN
- China
- Prior art keywords
- bifidus longum
- thalline
- cell
- functional food
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 11
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 22
- 230000007365 immunoregulation Effects 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims description 51
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 34
- 238000004321 preservation Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 239000000725 suspension Substances 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000003393 splenic effect Effects 0.000 description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 229950006238 nadide Drugs 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101710088194 Dehydrogenase Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 210000003371 toe Anatomy 0.000 description 5
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MCPIIUKZBQXOSD-UHFFFAOYSA-N 2-hydroxypropanoic acid;lithium Chemical compound [Li].CC(O)C(O)=O MCPIIUKZBQXOSD-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 244000071493 Iris tectorum Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides Bifidobacterium longum , which is characterized in that the preservation number of the Bifidobacterium longum is CGMCC No. 6283. The invention also provides a functional food composition and a preparation method thereof, wherein the method comprises the following steps: the cells of Bifidobacterium longum provided by the present invention are added to food. The invention also provides application of the bifidobacterium longum in preparing a functional food composition with an immunoregulation effect. The bifidobacterium longum provided by the invention has good immunoregulation effect.
Description
Technical field
The present invention relates to a kind of bifidus longum bb (Bifidobacterium longum) and application and functional food composition and preparation method thereof, particularly, relate to a kind of bifidus longum bb, contain functional food composition of this bifidus longum bb and preparation method thereof, and this bifidus longum bb has the application in the functional food of immunoregulation effect in preparation.
Background technology
Immunity is a kind of physiological function of human body, relates to non-specific immunity and specific immunity, and non-specific immunity does not need to contact in advance antigen, once pathogenic agent has entered body, can remove fast pathogenic agent.Phagocytic cell and natural killer cell all have the effect of removing and killing and wounding, and are the important members in non-specific immunity system.Specific immunity has the immunocyte of identifying specifically external foreign matter and having immunological memory ability---T lymphocyte and bone-marrow-derived lymphocyte.Information Conduction the most primary between immunity system is exactly cytokine.Every kind of cytokine has different stimulatory functions to different cell types, and they grow and functionally active by the inducing cell in conjunction with the specific receptors of cell surface.Human body relies on this identification of function " oneself " and " non-oneself " composition, thereby destroys and repel the antigenic substance that enters human body, or human body itself damaging cells and the tumour cell etc. that produce, to maintain the health of human body.Resist or prevent undesirable biological intrusion of microorganism or parasitic infection or other.
Bifidus bacillus is as human intestine's advantage physiology bacterium, played vital role safeguarding in host health, and bifidus bacillus can be brought into play the immunological enhancement function to body as integrated peptidoglycan, DNA by thalline and component thereof.Bifidobacterium strains has been proved to be has powerful anti-inflammatory feature, can regulate reparation to cytokine secretion unbalance; Also, by the cell levels impact on dendritic cell and vivo immuning system, bring into play humoral immunization and antibody secreted regulating effect.Bifidus bacillus security is higher, and separation and purification cost is low, and the prospect that sets it as immunomodulatory product will be very wide.
Summary of the invention
The object of this invention is to provide a kind of bifidus longum bb with immunoloregulation function.
To achieve these goals, on the one hand, the invention provides a kind of bifidus longum bb (Bifidobacterium longum), wherein, the deposit number of described bifidus longum bb is CGMCC No.6283.
Second aspect, the invention provides a kind of method of preparing functional food composition, and wherein, the method comprises: the thalline of bifidus longum bb provided by the invention is added in food.
The third aspect, the invention provides a kind of functional food composition of being prepared by method as above.
Fourth aspect, the invention provides bifidus longum bb as above and has the application in the functional food composition of immunoregulation effect in preparation.
Bifidus longum bb provided by the invention has good immunoregulatory effect.
Other features and advantages of the present invention are described in detail the embodiment part subsequently.
Biological preservation
Bifidus longum bb of the present invention (Bifidobacterium longum), be deposited in (address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center on June 25th, 2012, Institute of Microorganism, Academia Sinica, postcode: 100101) (depositary institution be abbreviated as CGMCC), deposit number is CGMCC No.6283.
Embodiment
Below the specific embodiment of the present invention is elaborated.Should be understood that, embodiment described herein only, for description and interpretation the present invention, is not limited to the present invention.
On the one hand, the invention provides a kind of bifidus longum bb (Bifidobacterium longum), wherein, the deposit number of this bifidus longum bb is CGMCC No.6283.
Bifidus longum bb of the present invention separates the ight soil from Bama County of Guangxi long lived elder.
Bifidus longum bb provided by the invention is through cultivating the viable bacteria body that can produce a large amount of bifidus longum bbs, and the method for described cultivation does not have special requirement, as long as making described bifidus longum bb propagation, and for example can be according to 10
7the inoculum size of CFU/mL in Medium of Bifidobacterium, and under anaerobic, is cultivated the inoculation of described bifidus longum bb after 8-72 hour at the temperature of 15-38 DEG C, obtains nutrient solution.The substratum of described bifidus bacillus can be the substratum that various applicable bifidus bacillus well known in the art is cultivated, can be for example milk and/or " milk-acid bacteria---Basic of Biology and application " (Yang Jiebin, light industry press, 1996 publish) described in milk-acid bacteria (MRS) substratum.
The present invention can further separate the viable bacteria body of the bifidus longum bb in above-mentioned nutrient solution, the method of described separation has no particular limits, as long as can be from nutrient solution enrichment thalline, for example can realize by method centrifugal and/or that filter, described condition centrifugal and described filtration can be known condition, and the present invention does not repeat them here.
Second aspect, the invention provides a kind of method of preparing functional food composition, and wherein, the method comprises: the thalline of bifidus longum bb provided by the invention is added in food.
The present inventor finds under study for action, no matter be the viable bacteria body of bifidus longum bb or the dead thalline of bifidus longum bb, or the mixing thalline of the viable bacteria body of bifidus longum bb and dead thalline all has good immunoregulation effect, the method for preparing functional food composition therefore providing comprises adds the viable bacteria body of bifidus longum bb and/or dead thalline in food to.Preferably, in order further to strengthen the immunoregulation effect of bifidus bacillus to body, the viable bacteria body of bifidus longum bb is added in food.
According to the present invention, the preparation method of the dead thalline of described bifidus longum bb has no particular limits, and for example, can, by lethal the viable bacteria body heating of the bifidus longum bb after above-mentioned cultivation, also can, by lethal its radiation, can also be exposed in oxygen lethal.The condition that described heating is lethal can comprise: temperature is 65-85 DEG C, and the time is 0.5-1.5h.
According to the present invention, although the thalline of bifidus longum bb is added in food, can realize object of the present invention, play immunoregulatory effect, but under preferable case, taking the gross weight of functional food composition as benchmark, the addition of the thalline of described bifidus longum bb is 10
2-10
11cFU/g, is preferably 10
6-10
9cFU/g.Under above-mentioned preferable case, the immunoregulation effect of functional food composition is more remarkable.
CFU(Colony-Forming Units, colony-forming unit) refer to viable bacteria number.Cultivate when counting viable bacteria, by single thalline or assemble agglomerating multiple thalline colony that growth and breeding forms on solid medium, be called colony-forming unit, express the quantity of viable bacteria with it.In the present invention, in the time that the concentration of the dead thalline of lactobacterium casei represents with CFU/g, refer to the dead thalline that obtains respective numbers by lethal the viable bacteria body of lactobacterium casei, and be dissolved in and in damping fluid, be mixed with desired concn.
In the present invention, food can be the food of any type, such as juice product, milk-product, bean product etc.Food also can be according to the difference of edible object and different.In described functional food composition, can also contain conventional additive, such as spices, mineral substance, VITAMIN, stablizer, thickening material, sanitas etc.
The third aspect, the invention provides a kind of functional food composition of being prepared by method as above.
The viable bacteria body of the bifidus longum bb that the functional food composition that meets above-mentioned requirements can comprise the nutrient solution of bifidus longum bb (for example through this bifidus longum bb ferment the cultured milk prod making), separate etc.
In the present invention, functional food composition also contains food, and food as previously mentioned, does not repeat them here.
Fourth aspect, the invention provides bifidus longum bb as above and has the application in the functional food composition of immunoregulation effect in preparation.
The present invention is further illustrated for following embodiment, but therefore do not limit the present invention.
In following preparation example, embodiment and comparative example:
Laboratory animal: Balb/c female mice, age in 6-8 week, weight 18-22g, SPF level, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..
Experimental strain: bifidus longum bb A is that (this bacterial strain was deposited in (address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center to bifidus longum bb of the present invention on June 25th, 2012, Institute of Microorganism, Academia Sinica, postcode: 100101) (depositary institution be abbreviated as CGMCC), deposit number is CGMCC No.6283); Positive strain (Bifidobacterium animalis ssp.Lactis BB12, animal bifid BB12) is purchased from Chr.Hansen company of Denmark.
Experiment reagent: ConA, Giemsa dyestuff, all purchased from Sigma company; Triton (Triton X-100), purchased from Merck company; Foetal calf serum (FBS), purchased from PAA company; MTT, purchased from Promega company; Sheep red blood cell (SRBC) (SRBC), purchased from Department Of Medicine, Peking University's animal center; Chicken red blood cell (CRBC), purchased from animal medicine institute of China Agricultural University; K562 cell, purchased from Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences's cell centre; Guinea pig serum, Dou Shi reagent, all purchased from China Medical Sciences Academy Medical Plants Institute; Skimming milk, purchased from Mengniu (group) limited-liability company; Hank ' s liquid, purchased from Hyclone company.
Serum lactic dehydrogenase (LDH) matrix liquid: contain DL-LACTIC ACID lithium 5 × 10
-2mol/L, INT(nitro tetrazolium chloride) 6.6 × 10
-4mol/L, PMS(phenazine methosulfate) 2.8 × 10-4mol/L, NAD(oxidized coenzyme I) 1.3 × 10-3mol/L, be dissolved in Tris-HCL(0.2mol/L, pH8.2), need matching while using.Wherein, PMS and INT are all purchased from Amresco company; NAD is purchased from Roche company; DL-LACTIC ACID lithium is purchased from Merck company.
Cell pyrolysis liquid: purchased from company difficult to understand of section hundred
The incomplete substratum of RPMI-1640: the RPMI-1640 culture medium dry powder (Gibco company) of 2 % by weight, 100IU/mL penicillin (Amresco company), 100mg/mL Streptomycin sulphate (Amresco company).
RPMI-1640 perfect medium: 10 volume % foetal calf serums (Hyclone company) are formulated by adding in the incomplete substratum of RPMI-1640.
NPNL substratum (neomycin-paromomycin-nalidixic acid-lithium chloride): peptone 10g, extractum carnis 3g, yeast soaks powder 5g, glucose 10g, Tryptones 5g, soy peptone 3g, beef liver powder 10g, Zulkovsky starch 0.5g, cysteine hydrochloride 0.5g, tween 80 1g, buffer A (K
2hPO
425g, KH
2pO
425g, H
2o250ml) 10ml, buffer B (MgSO
47H
2o0.5g, FeSO
47H
2o0.5g, NaCl0.5g, MnSO
40.337g, H
2o250ml) 5ml, distilled water 1000ml, adjusts pH to 7.2.Solid medium adds the agar powder of 1.5 % by weight.121 DEG C, 15min, sterilizing is for subsequent use.
Laboratory apparatus: vernier callipers, Mitutoyo company; UV-2102 ultraviolet spectrophotometer, UNICO company; Bio-rad Model680 microplate reader, Bio-rad company of the U.S.; MCO-15AC type CO
2incubator, SANYO company; High-pressure sterilizing pot, model is ZDX35BI, purchased from Shenan Medical Appliances Factory, Shanghai; Constant incubator, model is DNP9082, purchased from the grand experimental installation of upper Nereid company limited; Low-temperature and high-speed whizzer, model is 3K30: model is ACCULAB, purchased from German Satorious company.
Preparation example
(1) preparation of bifidus longum bb A viable bacteria body bacteria suspension: by bifidus longum bb A with the inoculum size of 1 volume % in liquid NPNL substratum in constant incubator 37 DEG C of anaerobism cultivate 14h, make bacteria concentration reach 10
9cFU/ml, bacterium liquid is at room temperature collected thalline with centrifugal 10 minutes of 4000g, thalline is with after the resuspended washed twice of stroke-physiological saline solution, with 12%(w/v) aseptic skimming milk adjust thalline, be mixed with respectively 2 × 10
2the bacteria suspension B1,2 × 10 of CFU/ml
4the bacteria suspension B2,2 × 10 of CFU/mL
6the bacteria suspension B3,2 × 10 of CFU/ml
7the bacteria suspension B4,2 × 10 of CFU/ml
8the bacteria suspension B5,2 × 10 of CFU/ml
9the bacteria suspension B6,2 × 10 of CFU/ml
10the bacteria suspension B7 and 2 × 10 of CFU/ml
11the bacteria suspension B8 of CFU/ml.
(2) preparation of the dead thalline bacteria suspension of bifidus longum bb A: get the bifidus bacillus A that is cultured to logarithmic phase in part above-mentioned (1), 70 DEG C of deactivations 1 hour, 4000g collects thalline for centrifugal 10 minutes, with 12%(w/v) aseptic skimming milk adjust thalline, be mixed with 2 × 10
8the bacteria suspension B9 of CFU/ml.
(3) bifidus longum bb A mixes the preparation of thalline bacteria suspension anyway: prepare viable bacteria body and the dead thalline of bifidus longum bb according to the method in (3) and (4), and be mixed with 2 × 10 according to the mass ratio of 1:1
8the bacteria suspension B10 of CFU/ml.
(4) prepare 2 × 10 according to the method for (1)
8the bacteria suspension B11 of CFU/ml animal bifid BB12.
(5) mouse is divided into 12 groups at random, and 10 every group, 22 ± 2 DEG C of room temperatures, 12 hours lamp photograph/dark cycle, freely drink water and ingest, and adaptability is raised after 5 days for subsequent use.
Embodiment 1-10
For the immunoregulation effect of bifidus longum bb A provided by the invention is described
(1) get 10 groups of mouse in preparation example (5), every day is disposable 0.2mL bacteria suspension B1, bacteria suspension B2, bacteria suspension B3, bacteria suspension B4, bacteria suspension B5, bacteria suspension B6, bacteria suspension B7, bacteria suspension B8, bacteria suspension B9 and the bacteria suspension B10 of gavaging respectively.Gavage 4 weeks continuously.
(2) delayed hypersensitivity (DTH) of SRBC induction
After being injected to mouse peritoneal, SRBC can produce delayed hypersensitivity by inducing mouse, stimulate T lymphopoiesis to become primed lymphocyte, after 4 days, can there is delayed hypersensitivity in visible attack portion position in the time attacking with SRBC again, again inject behind 24 hours of SRBC with injection again before toes thickness difference reflects the power of delayed hypersensitivity.
After gavaging bacteria suspension and finishing, give each mouse peritoneal injection 0.5mL2%(v/v) SRBC sensitization.After 4 days, with vernier caliper measurement left back toes thickness, at the subcutaneous injection 20%(v/v of measuring point) SRBC, every 20 μ L, measure left back toes portion thickness again after 24 hours, the replicate measurement of same position is averaged for 3 times.The level of response that represents DTH with the toes thickness difference before and after attacking, the results are shown in Table 1.
(3) half hemolytic dose (HC
50)
SRBC can stimulate B cell proliferation and be divided into plasmocyte as a kind of antigen, plasmocyte in lymphoglandula or Lymphoid tissue through 3-4 days maturations, can secrete antibody---the hemolysin corresponding with SRBC, and be discharged in body fluid, the content of measuring the hemolysin in mouse body fluid, objectively can prove to reflect the specific humoral immunity function of mouse.
Before above-mentioned mouse after gavaging bacteria suspension and finishing is slaughtered, to extract eyeball and get blood, blood sample is at room temperature placed blood coagulation in 3 hours, then be placed in 4 DEG C of refrigerators 12 hours, more centrifugal 10 minutes of 1000rpm at room temperature, upper serum collected, if be mixed with red corpuscle, recentrifuge, draws supernatant.The mensuration of serum hemolysin is carried out with evaluation technique specification (Ministry of Health of the People's Republic of China, 2003) according to protective foods inspection.500 times of the normal saline dilutions of 0.9 % by weight for serum sample, 10 times of normal saline dilutions for guinea pig serum.The serum sample of every milliliter of dilution adds 0.5mL10%SRBC(v/v), and 1mL guinea pig serum.Blank physiologic saline for substitute mice serum.Above system is hatched 30 minutes at 37 DEG C, sample 4 DEG C with 2000g centrifugal 10 minutes, to remove the not complete erythroprecipitin of haemolysis.Collect supernatant, mix with the ratio of 1:3 with reaction terminating liquid (Dou Shi reagent), under 540nm, measure optical density value with ultraviolet spectrophotometer, with OD
540nmrepresent the content of hemolysin in mice serum, wherein, the OD of test sample
540nmvalue is the OD with respect to the contrast of this step empty
540nmvalue, the results are shown in Table 1.
(4) drip sheet method measure macrophage phagocytic chicken red blood cell (CRBC) phagocytic rate
When after allosome material chicken red blood cell (CRBC) intrusion system, scavenger cell can be by assembling, and identifies and swallow three steps of elimination it is completed to phagocytosis.
Mouse is extractd eyeball and gets after blood, puts to death through cervical vertebra dislocation.In Bechtop, carefully cut off belly fur, expose peritonaeum, contain 5%(v/v to abdominal injection 4mL with asepsis injector) Hank ' the s liquid of foetal calf serum.Rub gently belly several under, with syringe sucking-off abdominal cavity liquid (about 2ml), wherein contain scavenger cell.The activity of macrophage phagocytic CRBCs adopts the dull and stereotyped Determination Staining (Ghoneum M, 2004) of Giemsa (main agents relating in the method has: Giemsa dyestuff), the CRBC number of engulfing with optics microscopic counting.The activate the phagocytic capacity of scavenger cell represents with the CRBC number that counting under 60 times of light microscopics is engulfed.100 scavenger cells of every slide counting, phagocytic rate is the shared per-cent of scavenger cell of engulfing CRBC in every 100 scavenger cells.The results are shown in Table 1.
(5) serum lactic dehydrogenase (LDH) method is measured natural killer cell (NK cell) activity
The endochylema of viable cell includes serum lactic dehydrogenase (LDH).Under normal circumstances, LDH can not permeate through cell membranes, and when cell is subject to after killing and wounding of NK cell, LDH is discharged into extracellular.LDH can make lithium lactate dehydrogenation, and then makes oxidized coenzyme I (NAD) be reduced into reduced coenzyme Ⅰ (NADH), and the latter is again through hydrogen carrier PMS(PMS) reduction INT(p-Iodonitrotetrazolium violet), INT accepts H
+be reduced into red-purple compound.By the content of colorimetric method for determining end product red-purple compound, just can reflect the cell concentration being killed and wounded, and then the killing activity of reflection natural killer cell.
Aseptic taking-up mouse spleen, is placed on 200 order metallic sieves, and screen cloth is immersed in the culture dish containing the incomplete substratum of RPMI-1640.Grind gently spleen tissue with glass syringe inner core, make it pass through 200 eye mesh screens, obtain monokaryon splenocyte.Splenocyte liquid is transferred to centrifuge tube, adds sterilized water and gently shakes 20 seconds with cracking red corpuscle wherein, adds immediately 2 × hank ' s liquid to recover former hydraulic pressure.The incomplete substratum washed twice of RPMI-1640 for remaining cell (splenic lymphocyte), is resuspended in RPMI-1640 perfect medium, and adjusting cell concn is 2 × 10
7individual/ml.According to (Trzonkowski P, 2004) in, disclosed colorimetry is used microplate reader under 490nm, to measure the activity (main agents relating in the method has: LDH matrix liquid) of LDH, using to the cell sensitive human cancer cell strain of NK K562 cell as target cell, represent the cell concentration being killed and wounded by the activity of the LDH discharging in the target cell solute being killed and wounded, the results are shown in Table 1.Natural killer cell activity is calculated by following formula:
Kill rate (%)=(test holes OD
490-Spontaneous release hole OD
490maximum release aperture OD of)/(
490-Spontaneous release hole OD
490) × 100.
Wherein, test holes OD
490represent that target cell is subject to the amount of killing and wounding of splenocyte of the present invention, Spontaneous release hole OD
490represent the kill and wound amount of target cell under state of nature, maximum release aperture OD
490represent the total kill amount of target cell.
(6) propagation of splenic lymphocyte
Adopt the propagation (main agents relating in the method has ConA, Triton X-100) of measuring splenic lymphocyte according to disclosed mtt assay in (Bujalance C, 2007).Under 570nm, measure the light absorption value in each hole by microplate reader, splenocyte propagation situation represents with proliferation rate, with following formula calculating, the results are shown in Table 1.
Proliferation rate=(stimulate hole OD
570-control wells OD
570)/control wells OD
570× 100%, wherein, stimulating hole is to use ConA to stimulate the culture hole of splenic lymphocyte, and control wells is not use ConA to stimulate the culture hole of splenic lymphocyte.
Comparative example 1
This comparative example is for illustrating the immunoregulation effect of positive control bacterial strain
Mensuration according to the method in embodiment 1-10 to the delayed allergy (DTH) that laboratory animal is fed, SRBC induces, the mensuration of half hemolytic dose (HC50), the mensuration of dripping the phagocytic rate of sheet method mensuration macrophage phagocytic chicken red blood cell (CRBC), serum lactic dehydrogenase (LDH) method are measured the mensuration of the propagation of the active mensuration of natural killer cell (NK cell) and splenic lymphocyte, different, that gavage to laboratory animal is bacteria suspension B11.Test result is in table 1.
Comparative example 2
This comparative example is for illustrating the immunoregulation effect of mouse self under state of nature
Mensuration according to the method in embodiment 1-10 to the delayed allergy (DTH) that laboratory animal is fed, SRBC induces, the mensuration of half hemolytic dose (HC50), the mensuration of dripping the phagocytic rate of sheet method mensuration macrophage phagocytic chicken red blood cell (CRBC), serum lactic dehydrogenase (LDH) method are measured the mensuration of the propagation of the active mensuration of natural killer cell (NK cell) and splenic lymphocyte, different, gavage to laboratory animal for isodose 12%(w/v) skimming milk.Test result is in table 1.
Table 1
Can be found out by upper table 1, embodiment 1-10 is compared and can be found out with comparative example 2 respectively, adopt bifidus longum bb of the present invention (the mixing thalline of viable bacteria body, dead thalline, the dead thalline of the living) mouse of feeding, and by the test of each immune performance, toes thickness, half hemolytic dose, macrophage phagocytic rate, NK cell killing rate and the lymphocytic proliferation rate of mouse all has the increase of significance, illustrates that bifidus longum bb of the present invention has immunoregulatory effect.Embodiment 3-6 is compared and can be found out with embodiment 1 and embodiment 2 and embodiment 7 and embodiment 8 respectively, and taking the gross weight of mixture as benchmark, the addition of bifidus bacillus is 10
6-10
9when CFU/ml, more obvious to the immunoregulation effect of body; Embodiment 5 is compared and can be found out with embodiment 9 and embodiment 10 respectively, and the viable bacteria body of bifidus bacillus is more obvious to the immunoregulation effect of body.
Embodiment 5 is compared and can be found out with comparative example 1, and bifidus longum bb of the present invention is better than the immunoregulation effect of commercial strain animal bifid BB12 to body to the immunoregulation effect of body.
In sum, the mixing thalline of the thalline after viable bacteria body, the deactivation of bifidus longum bb provided by the invention and viable bacteria body and dead thalline all has immunoregulatory effect.
More than describe the preferred embodiment of the present invention in detail; but the present invention is not limited to the detail in above-mentioned embodiment, within the scope of technical conceive of the present invention; can carry out multiple simple variant to technical scheme of the present invention, these simple variant all belong to protection scope of the present invention.
It should be noted that in addition, each concrete technical characterictic described in above-mentioned embodiment, in reconcilable situation, can combine by any suitable mode, for fear of unnecessary repetition, the present invention is to the explanation no longer separately of various possible array modes.
In addition, also can carry out arbitrary combination between various embodiment of the present invention, as long as it is without prejudice to thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (7)
1. a bifidus longum bb (Bifidobacterium longum), is characterized in that, the deposit number of described bifidus longum bb is CGMCC No.6283.
2. a method of preparing functional food composition, is characterized in that, the method comprises: the thalline of bifidus longum bb claimed in claim 1 is added in food.
3. method according to claim 2, wherein, the viable bacteria body that the thalline of described bifidus longum bb is bifidus longum bb and/or dead thalline.
4. method according to claim 3, wherein, the viable bacteria body that the thalline of described bifidus longum bb is bifidus longum bb.
5. according to the method described in any one in claim 2-4, wherein, taking the gross weight of described functional food composition as benchmark, the addition of the thalline of described bifidus longum bb is 10
2-10
11cFU/g, is preferably 10
6-10
9cFU/g.
6. the functional food composition of being prepared by the method described in any one in claim 2-5.
7. bifidus longum bb claimed in claim 1 has the application in the functional food composition of immunoregulation effect in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310149307.3A CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310149307.3A CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104120093A true CN104120093A (en) | 2014-10-29 |
| CN104120093B CN104120093B (en) | 2016-12-28 |
Family
ID=51765724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310149307.3A Active CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104120093B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796606A (en) * | 2014-12-29 | 2016-07-27 | 广州海思医疗科技有限公司 | Probiotics composition for reducing risk of fetal congenital heart disease and detecting method thereof |
| CN107893044A (en) * | 2017-12-27 | 2018-04-10 | 江南大学 | One plant of bifidobacterium longum and its application |
| CN116042427A (en) * | 2021-10-28 | 2023-05-02 | 南京盛德生物科技研究院有限公司 | Bifidobacterium longum, screening method thereof and preparation method of lysate of fermentation product of saccharomyces cerevisiae |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649303A (en) * | 2009-05-08 | 2010-02-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Bifidobacterium, application thereof and food composition containing same |
| CN102018216A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Composition containing bifidobacteria for adjusting intestinal flora and enhancing immunity |
| CN102869365A (en) * | 2009-05-11 | 2013-01-09 | 雀巢产品技术援助有限公司 | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| CN103002901A (en) * | 2010-06-18 | 2013-03-27 | 雀巢产品技术援助有限公司 | L. johnsonii la1, b. longum ncc2705 and immune disorders |
-
2013
- 2013-04-26 CN CN201310149307.3A patent/CN104120093B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649303A (en) * | 2009-05-08 | 2010-02-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Bifidobacterium, application thereof and food composition containing same |
| CN102869365A (en) * | 2009-05-11 | 2013-01-09 | 雀巢产品技术援助有限公司 | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| CN102018216A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Composition containing bifidobacteria for adjusting intestinal flora and enhancing immunity |
| CN103002901A (en) * | 2010-06-18 | 2013-03-27 | 雀巢产品技术援助有限公司 | L. johnsonii la1, b. longum ncc2705 and immune disorders |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796606A (en) * | 2014-12-29 | 2016-07-27 | 广州海思医疗科技有限公司 | Probiotics composition for reducing risk of fetal congenital heart disease and detecting method thereof |
| CN107893044A (en) * | 2017-12-27 | 2018-04-10 | 江南大学 | One plant of bifidobacterium longum and its application |
| CN116042427A (en) * | 2021-10-28 | 2023-05-02 | 南京盛德生物科技研究院有限公司 | Bifidobacterium longum, screening method thereof and preparation method of lysate of fermentation product of saccharomyces cerevisiae |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104120093B (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
| JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
| RU2281326C2 (en) | BACTERIUM STRAIN Escherichia coli USEFUL IN NORMALIZATION OF GASTROINTESTINAL TRACT PHYSIOLOGICAL ACTIVITY, PROBIOTIC COMPOSITION FOR NORMALIZATION OF GASTROINTESTINAL TRACT PHYSIOLOGICAL ACTIVITY (VARIANTS), METHOD FOR PRODUCTION THEREOF AND METHOD FOR CULTURING OF BACTERIUM STRAIN Escherichia coli | |
| CN101649303B (en) | Bifidobacterium, application thereof and food composition containing same | |
| CN102292431A (en) | Novel lactobacillus plantarum and composition containing the same | |
| CN102533618A (en) | Lactobacillus plantarum CCFM8724 and application thereof | |
| JP2012533290A (en) | Novel Lactobacillus plantarum and composition containing the same | |
| JPWO2011111734A1 (en) | Lactic acid bacteria-containing preparation | |
| CN101144062A (en) | Lactobacillus casei strain and application for products thereof in bird immunity | |
| CN109666609A (en) | A kind of Rhodococcus ruber fermentation process and its application as adjuvant in animal vaccine | |
| KR101533602B1 (en) | Compositions for inducing an immune response of silkworm and silkworm having anitmicrobial induced an immune response by using the same | |
| CN109762760A (en) | A kind of preparation method and application of Bei Laisi bacillus DH82 and its antibacterial protein | |
| CN104120093A (en) | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof | |
| CN101606581B (en) | Green feed additive and preparation method thereof | |
| CN105327338B (en) | A kind of drug and preparation method thereof for treating ulcerative colitis | |
| CN102552894B (en) | Preparation method for snakehead virulent ascitesosis disease vaccine | |
| Unachukwu et al. | Evaluation of antimicrobial activities of fluted pumpkin leaf extract (Telfairia occidentalis) against selected pathogenic bacteria using standard drug | |
| CN102731612B (en) | A kind of preparation method of the outer whole protein extracting solution of born of the same parents preventing and treating Monochamus alternatus | |
| KR20240037981A (en) | Physiologically acceptable yeast compositions and uses thereof | |
| CN107213164A (en) | The preparation method of Tiny ecosystem soil compound | |
| Mohammed et al. | Lactobacillus salivarius bacteriocin and supernatant activity against Entamoeba histolytica in vitro and in vivo | |
| CN102702373A (en) | Whole peptidoglycan of lactobacillus cell wall and application in improving IEC (intestinal epithelial cell) antimicrobial peptide expression level thereof | |
| CN103007266B (en) | Predominant serum type vaccines in duck colibacillosis area, and preparation method and application thereof | |
| CN102058884B (en) | Grass carp injection vaccine synergist and preparation method thereof | |
| KR20170089602A (en) | Composition for preventing and improving of ruminants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ren Fazheng Inventor after: Zhao Liang Inventor after: Liu Songling Inventor before: Ren Fazheng |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160825 Address after: 100083 Haidian District Qinghua East Road, No. 17, Beijing Applicant after: China Agricultural University Address before: 100085, room 5, building 39, No. 203 West Road, Beijing, Haidian District Applicant before: Beijing Zhongtian Shenzhou Space Foods Technology Research Institute |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170427 Address after: 851400 A in Tibet District of Lhasa economic and Technological Development Zone Qionggang Lin Road East Road No. 6 Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY CO., LTD. Address before: 100083 Haidian District Qinghua East Road, No. 17, Beijing Patentee before: China Agricultural University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211014 Address after: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee after: QINGHAI TREASURE OF PLATEAU YAK MILK Co.,Ltd. Patentee after: RUOERBAO TREASURE OF PLATEAU YAK MILK Co.,Ltd. Address before: 851400 No.6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Tibet Patentee before: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee after: QINGHAI TREASURE OF PLATEAU YAK MILK CO.,LTD. Patentee after: Ruoergai Plateau Zhibao yak milk nutritional food Co.,Ltd. Address before: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee before: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee before: QINGHAI TREASURE OF PLATEAU YAK MILK CO.,LTD. Patentee before: RUOERBAO TREASURE OF PLATEAU YAK MILK CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder |